MOONLAKE IMMUNOTHERAPEUTICS's ticker is and the CUSIP is 61559X104. A total of 85 filers reported holding MOONLAKE IMMUNOTHERAPEUTICS in Q2 2023. The put-call ratio across all filers is - and the average weighting 1.2%.
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 21,751,284 | $1,109,315,484 | 30.92% |
| Cormorant Asset Management, LP | 8,142,100 | $415,247,100 | 23.26% |
| Ally Bridge Group (NY) LLC | 91,413 | $4,662,063 | 5.65% |
| Ghost Tree Capital, LLC | 330,000 | $16,830,000 | 5.56% |
| Finepoint Capital LP | 302,000 | $15,402,000 | 5.33% |
| 5AM Venture Management, LLC | 357,486 | $18,231,786 | 4.54% |
| Altium Capital Management LP | 88,000 | $4,488,000 | 3.40% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 200,000 | $10,200,000 | 3.16% |
| MPM BioImpact LLC | 295,111 | $15,050,661 | 3.03% |
| HighVista Strategies LLC | 129,722 | $6,615,822 | 3.03% |